精元康胶囊对不同治疗方案的116例HIV/AIDS患者白细胞水平影响的随机对照研究

蒋士卿; 孙宏新; 徐英敏; 裴俊文; 王红玲

您当前的位置：

首页 >

文章列表页 >

精元康胶囊对不同治疗方案的116例HIV/AIDS患者白细胞水平影响的随机对照研究

更新时间：2024-09-23

- 精元康胶囊对不同治疗方案的116例HIV/AIDS患者白细胞水平影响的随机对照研究
- Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling
- 中国实验方剂学杂志 2010年16卷第14期页码：201-203
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家科技部"十五"科技攻关计划(2004BA719A09-0203)
- DOI：
  中图分类号：
- 纸质出版日期：2010
- 稿件说明：
移动端阅览
蒋士卿, 孙宏新, 徐英敏, 等. 精元康胶囊对不同治疗方案的116例HIV/AIDS患者白细胞水平影响的随机对照研究[J]. 中国实验方剂学杂志, 2010,16(14):201-203.

JIANG Shi-qing, SUN Hong-xin, XU Ying-min, et al. Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(14): 201-203.
蒋士卿, 孙宏新, 徐英敏, 等. 精元康胶囊对不同治疗方案的116例HIV/AIDS患者白细胞水平影响的随机对照研究[J]. 中国实验方剂学杂志, 2010,16(14):201-203. DOI：

JIANG Shi-qing, SUN Hong-xin, XU Ying-min, et al. Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(14): 201-203. DOI：

摘要

目的: 观察精元康胶囊对艾滋病外周血象低下的治疗效果。方法: 选用中药制剂精元康胶囊＋利可君片模拟剂与HAART疗法同时服用组患者58例

并与西药利可君片＋精元康胶囊模拟剂与HAART疗法同时服用患者58例

采用随机、双盲、双模拟剂的临床试验方法

均系统服药6个月

定期检测患者外周血象

以观察精元康胶囊对艾滋病不同程度的白细胞低下的治疗效果。结果: 精元康胶囊治疗艾滋病外周血象低下效果良好

服用含齐多夫定(AZT)HAART方案的患者与服用不含齐多夫定(AZT)的HAART方案者比较

均显示出提升白细胞作用。精元康胶囊临床安全有效

治疗中及后期随访均未观察到本制剂引起的毒副作用和不良反应。结论: 精元康胶囊可有效治疗艾滋病患者外周血象低下。

Abstract

Objective: To observe the the therapeutic effect on peripheral blood leukocyte reduction of AIDS by Jingyuankang Capsule. Method: 116 cases of HIV/AIDS patients were divided into two groups: 58 cases in the treatment were treated by Jingyuankang Capsule and likejun mimic tablet with HAART therapy

and the other 58 cases in the control by likejun tablet and mimic Jingyuankang Capsules with HAART. The design was a randomized double-blind research

and 6 months as a course. Peripheral blood leukocytes were monitored for these cases. Result: Jingyuankang Capsule treatment for AIDS showed good effect

whether they had taken with AZT (HAART) or not. HAART scheme showed that it could improve peripheral blood leukocytes. Jingyuankang Capsule appeared safe and effective. Through clinical investigation and follow-up the capsule showed no toxicity and adverse reaction. Conclusion: Jingyuankang Capsules can effectively treat AIDS patients with reduction in peripheral blood leukocyte.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

精元康胶囊对不同治疗方案的116例HIV/AIDS患者白细胞水平影响的随机对照研究